Five Prime Therapeutics Inc (NASDAQ:FPRX) has been given a consensus recommendation of “Buy” by the eleven brokerages that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and seven have issued a buy recommendation on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $24.29.

A number of equities analysts have commented on FPRX shares. ValuEngine raised Five Prime Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, November 26th. Cowen reaffirmed a “buy” rating on shares of Five Prime Therapeutics in a research note on Wednesday, February 27th. BidaskClub raised Five Prime Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, January 22nd. Zacks Investment Research raised Five Prime Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a research note on Monday, January 21st. Finally, Wedbush raised Five Prime Therapeutics from a “neutral” rating to an “outperform” rating and set a $16.00 price target on the stock in a research note on Thursday, January 17th.

Shares of NASDAQ FPRX traded up $0.32 during trading hours on Friday, reaching $12.72. 553,573 shares of the stock traded hands, compared to its average volume of 292,799. The stock has a market cap of $451.40 million, a price-to-earnings ratio of -3.08 and a beta of 3.16. Five Prime Therapeutics has a 52-week low of $7.84 and a 52-week high of $19.95.

Five Prime Therapeutics (NASDAQ:FPRX) last announced its quarterly earnings data on Tuesday, February 26th. The biotechnology company reported ($1.12) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.32) by $0.20. Five Prime Therapeutics had a negative return on equity of 44.55% and a negative net margin of 281.64%. As a group, sell-side analysts anticipate that Five Prime Therapeutics will post -3.99 earnings per share for the current fiscal year.

Institutional investors have recently made changes to their positions in the business. Quantamental Technologies LLC purchased a new position in Five Prime Therapeutics in the 4th quarter worth approximately $58,000. Jane Street Group LLC purchased a new position in Five Prime Therapeutics in the 4th quarter worth approximately $110,000. Virtu Financial LLC purchased a new position in Five Prime Therapeutics in the 4th quarter worth approximately $113,000. Metropolitan Life Insurance Co. NY increased its stake in Five Prime Therapeutics by 456.2% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 13,283 shares of the biotechnology company’s stock worth $124,000 after purchasing an additional 10,895 shares during the period. Finally, D. E. Shaw & Co. Inc. purchased a new position in Five Prime Therapeutics in the 4th quarter worth approximately $140,000. 86.30% of the stock is currently owned by institutional investors and hedge funds.

About Five Prime Therapeutics

Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics. The company's product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor.

See Also: Return on Investment (ROI) Defined, Explained

Analyst Recommendations for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.